Ofichem agrees to acquire US CDMO Kinentia Biosciences

Ofichem has agreed to acquire US-based Kinentia Biosciences, expanding its drug substance development capabilities and establishing a transatlantic CDMO platform spanning the United States and Europe.

The acquisition of the Rensselaer, New York-based company will give the Dutch pharmaceutical services group an operational presence in the US and add early-stage development expertise to its existing process development, GMP manufacturing and commercial supply operations. Completion remains subject to approval from the Committee on Foreign Investment in the United States (CFIUS) and other customary closing conditions.

Founded in 2007, Kinentia supports pharmaceutical and biotechnology companies with early-stage development, preclinical programmes and clinical development activities. Following completion, its customers will be able to access Ofichem’s wider drug substance network as their programmes advance, including process scale-up, regulatory support and GMP manufacturing at Ofichem’s FDA-inspected facility in Ter Apel, the Netherlands.

The combined network will operate across three locations: New York, Ter Apel and Uppsala, Sweden. Each site will contribute different scientific and manufacturing capabilities, supporting programmes from early scientific and analytical development through to process development, scale-up and GMP production.

Building US and European manufacturing capabilities

The acquisition is intended to give Ofichem closer access to existing US customers and Kinentia’s biotechnology customer base, while offering customers greater flexibility over where development and manufacturing activities take place.

The group said the expansion would support pharmaceutical companies reviewing supply chain resilience and regional manufacturing strategies, including the potential to develop manufacturing options in both the US and Europe.

Dr Weite Oldenziel, CEO of the Ofichem Group, said: “The acquisition of Kinentia represents an important milestone in Ofichem’s continued development. It strengthens our presence in the United States and complements our established European development and manufacturing capabilities. We are building one organisation with one knowledge base, able to support customers from the first development decisions through to commercial supply.”

Ofichem also intends to explore opportunities to establish US capabilities for controlled substances, subject to the necessary licences and approvals. The company already has experience working with highly regulated products in Europe.

Expanding specialist chemistry expertise

Kinentia will broaden Ofichem’s scientific offering through additional expertise in polysaccharides, small peptides and complex new chemical entities.

These capabilities complement the group’s established work in small molecules, highly potent compounds requiring OEB 3–5 containment, oligonucleotides and targeted protein degradation technologies, including proteolysis-targeting chimeras (PROTACs).

Alessia Cogotti, managing director of Ofichem’s Drug Substance Business Unit, said: “Kinentia brings highly complementary capabilities and experience to our Drug Substance business and strengthens our position in the United States. Its expertise in early-stage development, complex chemistry and complementary modalities broadens our scientific offering, while Ofichem’s existing GMP and commercial manufacturing capabilities allow us to support programmes as they progress towards commercialisation.”

She added: “Keeping scientific and process knowledge within one accountable organisation provides greater continuity as programmes develop, reducing the risks associated with handovers between independent providers and creating a more connected path from early development through to commercial manufacturing.”

Connecting early development with commercial supply

Kinentia president and CEO Dr Dave Fairfax said: “For our team and our customers, the fit with Ofichem is strong. We share a commitment to quality, scientific expertise and long-term customer relationships. Joining the group gives Kinentia access to a wider scientific network and a route into commercial manufacturing, while preserving the specialist approach that has shaped our business since 2007.”

The acquisition builds on Ofichem’s expansion of its European development and manufacturing network and its strategy of investing in specialist capabilities and key pharmaceutical markets.

The wider group also operates sourcing and distribution activities from the Netherlands, China and Germany, alongside drug product formulation and manufacturing operations in Nijmegen and Leiden in the Netherlands.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox